Will Mersana Therapeutics Inc (NASDAQ:MRSN) Run Out of Steam Soon? Short Interest Is Down

June 2, 2018 - By Rene Maslow

The stock of Mersana Therapeutics Inc (NASDAQ:MRSN) registered a decrease of 4.03% in short interest. MRSN’s total short interest was 1.84 million shares in June as published by FINRA. Its down 4.03% from 1.91M shares, reported previously. With 60,900 shares average volume, it will take short sellers 30 days to cover their MRSN’s short positions. The short interest to Mersana Therapeutics Inc’s float is 18.69%.

The stock decreased 1.10% or $0.23 during the last trading session, reaching $20.7. About 155,804 shares traded or 23.06% up from the average. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since June 2, 2017 and is . It has underperformed by 12.57% the S&P500.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $474.07 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: Streetinsider.com which released: “Mersana Therapeutics (MRSN) to Present Interim Phase 1 Data on XMT-1522 at ASCO” on May 22, 2018, also Benzinga.com with their article: “Baird: Mersana Is A Buy On Differentiated Platform For Cancer Indications” published on May 08, 2018, Nasdaq.com published: “Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference” on May 24, 2018. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: Globenewswire.com and their article: “Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates” published on May 07, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” with publication date: May 25, 2018.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: